Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC07-523LS and PGT121.414.LS in HIV-1 Infection During Analytic Treatment Interruption
NCT06987318Phase 1Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of VRC07-523LS and PGT121 in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of participants experiencing a Grade >=3 Adverse Event (AE) or Serious Adverse Events (SAE) related to study treatment at 36 weeks and Proportion of study participants experiencing viral suppression at 62 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
VRC07-523LSPGT121
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06987318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06987318.